The Latest Breaking News from Pfizer

The stock market traded mixed on Friday on hot job numbers, closing out the week with gains. AMC popped on earnings beat.

Rumors that Pfizer is in "advanced talks" to acquire Global Blood Therapeutics for about $5 billion sent GBT stock flying Friday.

Alnylam stock cooled Friday as one expert argued the company will have to run a second study of its cardiomyopathy drug to gain traction.

There were 1.26 million courses dispensed last month, a 37% increase when compared to June numbers.

Someone with a lot of money to spend has taken a bullish stance on Pfizer (NYSE:PFE). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Paxlovid good at stopping hospitalisation for high-risk groups, despite occasional rebound

The world is watching the Jan. 6 hearings in the United States in dismay and contemplating the possible end of the American democratic experiment.

21.2 million Americans received their second booster by the end of July.

After taking Paxlovid, Biden tested negative for several days, then positive. He's not the only one

The “living with COVID” strategy being pursued by many countries relies heavily on two key pillars. First, that vaccines continue to protect most people from severe disease. And second, that where they don’t, people will receive antiviral treatments. But are the antivirals currently available sufficiently effective, accessible and durable?

The Food and Drug Administration reportedly has a new strategy for rolling out new booster shots that should bring needed clarity to COVID vaccination in the U.S. Going forward, most Americans will get the same advice about when to get their next shots.